Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of “Moderate Buy” from Brokerages

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price target […]

Leave a Reply

Your email address will not be published.

Previous post Agape ATP (NASDAQ:ATPC) and P3 Health Partners (NASDAQ:PIII) Financial Comparison
Next post Head to Head Comparison: CloudCommerce (CLWD) versus The Competition